Oragenics's New Preclinical Data Supports Its Approach For COVID-19 Vaccine Development
Oragenics Inc's (NYSE: OGEN) stabilized pre-fusion spike protein trimer generates neutralizing antibodies in mice after immunization against SARS-CoV-2 when administered with several intramuscular (IM) and intranasal (IN) adjuvants.
The expression platform is developed by Oragenics' Canadian collaborator and licensed from the National Institutes of Health (NIH).
The platform will expedite the evaluation of hybrid SARS-CoV-2 antigen candidates scheduled to be evaluated in a hamster viral challenge study beginning with dosing at the end of this month.
The mouse immunogenicity study enabled the down-selection of the four adjuvant candidates tested thus far, with two being advanced to assess inhibition of viral replication in hamsters and IND-enabling toxicology studies.
Oragenics plans to file an IND application with the FDA in Q1 of 2022.
Related Content: Oragenics Announces Licensing, Material Transfer Pact For Rapid Development Of COVID-19 Vaccine
Price Action: OGEN shares are up 4.10% at $0.71 during the market session on the last check Monday.
See more from Benzinga
Catalent Makes Strategic Move For Consumer Health Business With Bettera Deal
UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
